These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35923309)

  • 1. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine.
    Xie X; Zou J; Kurhade C; Liu M; Ren P; Shi PY
    bioRxiv; 2022 Aug; ():. PubMed ID: 35923309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine.
    Xie X; Zou J; Kurhade C; Liu M; Ren P; Pei-Yong Shi
    Cell Rep; 2022 Nov; 41(9):111729. PubMed ID: 36402138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
    Kurhade C; Zou J; Xia H; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
    Nat Commun; 2022 Jun; 13(1):3602. PubMed ID: 35739094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
    Zou J; Kurhade C; Xia H; Liu M; Xie X; Ren P; Shi PY
    Nat Commun; 2022 May; 13(1):2956. PubMed ID: 35618703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone.
    Santos da Silva E; Servais JY; Kohnen M; Arendt V; Gilson G; Staub T; Seguin-Devaux C; Perez-Bercoff D
    Curr Issues Mol Biol; 2023 Feb; 45(2):1741-1761. PubMed ID: 36826057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2.
    Xia H; Zou J; Kurhade C; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
    Cell Host Microbe; 2022 Apr; 30(4):485-488.e3. PubMed ID: 35245438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.
    Xia H; Yeung J; Kalveram B; Bills CJ; Chen JY; Kurhade C; Zou J; Widen SG; Mann BR; Kondor R; Davis CT; Zhou B; Wentworth DE; Xie X; Shi PY
    Emerg Microbes Infect; 2023 Dec; 12(1):e2161422. PubMed ID: 36594261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
    Wang W; Lusvarghi S; Subramanian R; Epsi NJ; Wang R; Goguet E; Fries AC; Echegaray F; Vassell R; Coggins SA; Richard SA; Lindholm DA; Mende K; Ewers EC; Larson DT; Colombo RE; Colombo CJ; Joseph JO; Rozman JS; Smith A; Lalani T; Berjohn CM; Maves RC; Jones MU; Mody R; Huprikar N; Livezey J; Saunders D; Hollis-Perry M; Wang G; Ganesan A; Simons MP; Broder CC; Tribble DR; Laing ED; Agan BK; Burgess TH; Mitre E; Pollett SD; Katzelnick LC; Weiss CD
    Cell Host Microbe; 2022 Dec; 30(12):1745-1758.e7. PubMed ID: 36356586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses.
    Branche AR; Rouphael NG; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Anderson EJ; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Malkin E; Bethony JM; Walsh EE; Graciaa DS; Samaha H; Sherman AC; Walsh SR; Abate G; Oikonomopoulou Z; El Sahly HM; Martin TCS; Rostad CA; Smith MJ; Ladner BG; Porterfield L; Dunstan M; Wald A; Davis T; Atmar RL; Mulligan MJ; Lyke KE; Posavad CM; Meagher MA; Stephens DS; Neuzil KM; Abebe K; Hill H; Albert J; Lewis TC; Giebeig LA; Eaton A; Netzl A; Wilks SH; Türeli S; Makhene M; Crandon S; Lee M; Nayak SU; Montefiori DC; Makowski M; Smith DJ; Roberts PC; Beigel JH;
    medRxiv; 2022 Jul; ():. PubMed ID: 35898343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.
    Kurhade C; Zou J; Xia H; Liu M; Chang HC; Ren P; Xie X; Shi PY
    Nat Med; 2023 Feb; 29(2):344-347. PubMed ID: 36473500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.